안면 홍조 치료제 시장은 예측기간(2025년-2034년)에 환자수 증가, 기술의 진보, 신치료법의 등장 등 큰 촉진요인에 의해 더욱 성장할 전망입니다.
안면 홍조는 주로 호르몬 요법에 의해 관리되며, 이는 증상을 일으키는 호르몬 변동을 조절하는 데 도움이 됩니다. 가장 널리 사용되는 치료법에는 자궁을 가진 여성에서 프로게스틴과 함께 사용되는 에스트로겐 요법과 새로 FDA 승인된 VEOZAH(fezolinetant)가 포함됩니다. VEOZAH는 시상하부의 체온조절을 조절하여 표적을 좁힌 완화를 제공하여 임상시험에서 빈도와 중증도를 대폭 완화함과 동시에 양호한 안전성 프로파일을 보여줍니다. 다른 옵션으로는 선택적 세로토닌 재 흡수 억제제(SSRI)/세로토닌 노르 에피네프린 재 흡수 억제제(SNRI), gabapentin, clonidine과 같은 비 호르몬 약물 외에도 생활 습관 개선 및 인지 행동 치료이 포함됩니다. VEOZAH는 호르몬 요법 이외에 치료 옵션을 확대하고 호르몬 요법을 사용할 수 없거나 선택하지 않는 여성의 요구에 부응한다는 점에서 큰 진보를 보여줍니다.
지속적인 연구와 헌신적인 노력을 통해 미래는 더욱 효과적인 치료법과 궁극적으로 이 어려운 증상에 대한 잠재적인 치료법의 확립이 기대됩니다. DelveInsight에 따르면 안면 홍조 치료제의 주요 7개 시장은 예측 기간(2025년-2034년)으로 크게 변화할 전망입니다.
이 보고서는 안면 홍조의 주요 7개 시장(미국, 독일, 스페인, 이탈리아, 프랑스, 영국, 일본)에 대한 조사 분석을 통해 각국 시장 규모, 역학 데이터, 각 치료법 시장 점유율, 신치료법, 암멧 필요 등의 정보를 제공합니다.
DelveInsight's comprehensive report titled "Hot Flashes - Market Insights, Epidemiology, and Market Forecast - 2034" offers a detailed analysis of hot flashes. The report presents historical and projected epidemiological data covering total incident cases of menopause, total diagnosed prevalent cases of hot flashes, severity-specific diagnosed prevalent cases of hot flashes and treated cases of hot flashes. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020 to 2034.
The report analyzes the existing treatment practices and unmet medical requirements in hot flashes. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.
Hot Flashes Overview
Hot flashes are sudden, intense sensations of heat, often accompanied by flushing, sweating, and sometimes chills, that result from hormonal changes affecting the body's temperature regulation. They are most commonly linked to the menopause transition but can also occur due to medical treatments, hormonal disorders, or other underlying conditions. Severity can vary, ranging from mild discomfort to significant disruption of sleep, daily activities, and work performance. Hot flashes typically begin in midlife for women, coinciding with declining estrogen levels, but can occur earlier in cases of premature menopause or certain medical interventions. While the exact mechanisms are not fully understood, changes in hypothalamic thermoregulation play a key role. Early-onset or unusually severe cases may warrant evaluation for alternative or secondary causes.
Hot Flashes Diagnosis and Treatment Overview
Hot Flashes are diagnosed primarily through clinical evaluation, supported by a thorough patient history and familiarity with menopausal or hormone-related symptoms. There are no definitive laboratory or imaging tests to confirm the diagnosis; however, hormone level assessments may help identify underlying causes such as menopause, premature ovarian insufficiency, or low testosterone in men. Additional testing is guided by the patient's age, medical history, and associated symptoms to rule out secondary conditions like thyroid disease or certain tumors.
Treatment for hot flashes varies widely between individuals, with no single approach universally effective. Most therapies focus on reducing episode frequency and severity, improving sleep, and enhancing quality of life. The optimal regimen often requires collaboration between patient and clinician, considering symptom burden, health status, and treatment preferences. Core options include hormonal therapy, non-hormonal medications such as SSRIs/SNRIs, gabapentin, or the neurokinin-3 receptor (NK-3) antagonist fezolinetant, as well as lifestyle modifications. These may be used alone or in combination. Supportive measures, such as cooling strategies, stress reduction techniques, and cognitive-behavioral therapy, can further help patients manage symptoms and maintain daily function.
The epidemiology section of the hot flashes market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.
This section also presents the total prevalence rate of hot flashes in menopause, supported by relevant tables and graphs to provide a clear and concise understanding of the data. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.
Key Findings
The hot flashes therapeutics market is further expected to increase by the major drivers, such as the rising prevalent population, technological advancements, and upcoming therapies in the forecast period (2025-2034).
Hot flashes are managed primarily through hormonal therapy, which helps regulate the hormonal fluctuations driving symptoms. The most widely used treatments include estrogen therapy, often combined with progestin in women with a uterus, and the newly FDA-approved VEOZAH (fezolinetant), the first non-hormonal, NK-3 receptor antagonist for hot flashes. VEOZAH offers targeted relief by modulating hypothalamic thermoregulation, significantly reducing frequency and severity in clinical trials, with a favorable safety profile. Additional options include non-hormonal medications such as Selective Serotonin Reuptake Inhibitors (SSRIs)/ Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), gabapentin, and clonidine, as well as lifestyle modifications and cognitive-behavioral therapy. VEOZAH represents a major advancement, expanding treatment options beyond hormones and addressing the needs of women who cannot or choose not to use hormonal therapy.
With ongoing research and continued dedication, the future holds promise for even more effective treatments and, ultimately, a potential cure for this challenging condition. According to DelveInsight, the hot flashes market in the 7MM is expected to change significantly during the forecast period (2025-2034).
Marketed Drugs
VEOZAH (fezolinetant): Astellas Pharma
VEOZAH, developed by Astellas Pharma and generically known as fezolinetant, is the first and only FDA-approved non-hormonal oral therapy for managing hot flashes in menopausal women. By targeting neurokinin-3 receptors in the brain, it addresses the underlying thermoregulatory dysfunction caused by hormonal changes, rather than simply masking symptoms.
LYNKUET (elinzanetant): Bayer
LYNKUET, generically known as elinzanetant, is an innovative, first-in-class, non-hormonal oral therapy in development for managing hot flashes in menopausal women. By dual-blocking neurokinin-1 and neurokinin-3 receptors in the brain, it directly targets the central thermoregulatory disruptions triggered by hormonal changes. This mechanism offers the potential to treat the underlying cause of symptoms, positioning LYNKUET as a promising next-generation option beyond conventional symptom relief.
Emerging Drugs
DONESTA (estetrol): Estetra/ Gedeon Richter
DONESTA, developed by Gedeon Richter, is an investigational therapy for the treatment of hot flashes and other menopause-related symptoms. It is an estetrol-containing, non-hormonal selective estrogen receptor modulator (SERM)-like product designed to target the underlying mechanisms of thermoregulatory dysfunction in menopause, with the aim of providing a safer and more targeted alternative to conventional hormone-based therapies.
In February 2025, the European Medicines Agency (EMA) accepted Gedeon Richter's Marketing Authorization Application (MAA) for DONESTA (estetrol-containing mono product) for the management of menopausal symptoms, marking the start of the formal regulatory evaluation process in the European Union.
Asimadoline (TP0052): Tioga Pharmaceuticals
Asimadoline (TP0052), developed by Tioga Pharmaceuticals, is an oral, non-hormonal investigational therapy being explored for the treatment of vasomotor symptoms such as hot flashes in post-menopausal women. It acts as a selective κ-opioid receptor agonist, targeting neurochemical pathways involved in thermoregulation, with the goal of addressing the underlying mechanisms driving symptom generation rather than merely reducing their external manifestations.
NOE-115: Noema Pharma
NOE-115, developed by Noema Pharma, is an innovative, oral, non-hormonal investigational therapy designed to treat vasomotor symptoms, including hot flashes and night sweats, in postmenopausal women. As a broad-spectrum monoamine modulator, it targets multiple neurotransmitter pathways to potentially address the root neurochemical drivers of thermoregulatory disruption, offering symptom relief as well as improvements in weight control, energy levels, and cognitive function.
Hot Flashes Market Segmentation
DelveInsight's "Hot Flashes - Market Insights, Epidemiology, and Market Forecast - 2034" report provides a detailed outlook of the current and future hot flashes market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.
Hot Flashes Market Size by Countries
The hot flashes market size is assessed separately for various countries, including the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2024, the United States held a significant share of the overall 7MM (Seven Major Markets) hot flashes market, primarily attributed to the country's higher prevalence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.
This section focuses on the sales uptake of potential hot flashes drugs that have recently been launched or are anticipated to be launched in the hot flashes market between 2025 and 2034. It estimates the market penetration of hot flashes drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the hot flashes market.
The emerging hot flashes therapies are analyzed based on various attributes such as efficacy and safety in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the hot flashes market.
Hot Flashes Market Access and Reimbursement
DelveInsight's "Hot Flashes - Market Insights, Epidemiology, and Market Forecast - 2034" report provides a descriptive overview of the market access and reimbursement scenario of hot flashes. This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.
KOL Views
To keep up with current hot flashes market trends and to fill gaps in secondary findings, we interview KOLs' and SMEs' working in the hot flashes domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or hot flashes market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the hot flashes unmet needs.
Hot Flashes: KOL Insights
DelveInsight's analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as University of Texas MD Anderson Cancer Center, US; University Medical Center Hamburg-Eppendorf, Germany; PSL Research University, France; University of Campania "Luigi Vanvitelli, Italy; Complutense University, Spain; Liverpool John Moores University, UK; Keio University School of Medicine, Japan; among others.
As per KOLs from the US, "Hot flashes significantly impact quality of life during menopause, with symptoms varying widely in frequency and severity. Experts emphasize that non-hormonal treatments, such as neurokinin receptor antagonists, are reshaping management by targeting the underlying thermoregulatory pathways. Leading voices also highlight the importance of personalized approaches, given the diverse symptom profiles and treatment needs among menopausal women."
As per KOLs from Germany, "Despite advances in menopausal care, a significant unmet need remains for effective, non-hormonal therapies that address hot flashes without increasing risks related to hormone replacement. Experts stress the importance of integrating multidisciplinary support, including mental health and lifestyle interventions, to better manage the broad impact of vasomotor symptoms."
As per KOLs from Japan, "The relatively low reported prevalence of hot flashes may mask under diagnosis and cultural stigma around menopause symptoms. Specialists highlight the need for increased awareness and accessible treatment options, especially non-hormonal therapies, to meet the unique clinical and social challenges faced by Japanese women during menopause."
Competitive Intelligence Analysis
We conduct a competitive and market intelligence analysis of the hot flashes. Market, utilizing various Competitive Intelligence tools such as SWOT analysis and market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.
Hot Flashes Pipeline Development Activities
The report offers an analysis of therapeutic candidates in Phase II and III stages and examines companies involved in developing targeted therapeutics for hot flashes. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.
Pipeline Development Activities
The report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging hot flashes therapies.
The primary treatment goals for hot flashes are to reduce the frequency and severity of vasomotor symptoms, alleviate associated discomfort such as night sweats and sleep disturbances, and improve overall quality of life. Additional objectives include addressing underlying hormonal or neurological causes, minimizing side effects from therapies, and providing long-lasting symptom relief. Treatments aim to enable women to maintain daily functioning and well-being while reducing the need for frequent medication adjustments or invasive interventions.
Managing hot flashes presents several challenges, including wide variability in symptom severity and patient response to treatment. Hormonal therapies, while effective, may not be suitable for all due to contraindications or safety concerns. Non-hormonal options often provide only partial relief and may require ongoing adjustments. Additionally, underreporting and cultural stigma can delay diagnosis, while limited awareness among healthcare providers can hinder personalized treatment. Access to comprehensive care and long-term management strategies remains inconsistent, complicating effective symptom control.
Key factors driving the growth of the hot flashes market include increasing awareness of menopausal health issues, a growing aging female population, and greater demand for effective non-hormonal treatment options. The approval and adoption of novel therapies like neurokinin receptor antagonists, advancements in personalized medicine, and expanding healthcare access also fuel market expansion. Additionally, ongoing research, improved patient education, and supportive regulatory environments enhance treatment availability and uptake.
The hot flashes market and epidemiology forecast report provides clients with comprehensive insights into disease prevalence, patient demographics, and market trends. It enables identification of unmet needs, assessment of competitive landscapes, and strategic planning for product development and market access. The report supports informed decision-making by offering analysis of regulatory frameworks, emerging therapies, and forecasted growth, helping stakeholders optimize investments and policy strategies.